Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Glutathione and SR-9011 — mechanism, side effects, legal status, and pricing.
Glutathione is an endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) that serves as the principal intracellular antioxidant in mammalian cells. It is not FDA-approved as a drug in the US; parenteral glutathione is used off-label (and in some compounding settings) for oxidative stress, hepatic support, and — controversially — skin lightening. The FDA has warned against injectable glutathione for skin lightening (2019) due to reports of serious adverse events.
SR-9011 is a synthetic small-molecule REV-ERB (Rev-erbα/β) agonist — not a peptide — studied preclinically as a circadian/metabolic modulator. It has no human data of any kind, no regulatory approval, and is WADA-prohibited at all times. Note: it is frequently confused with "Stenabolic," which is properly its analog SR9009, not SR-9011.
Glutathione
SR-9011
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Glutathione
SR-9011
COA corpus from Disclosed Labs — independently tested batches only.
Glutathione
62
COAs
99.5%
Avg purity
10
Labs
SR-9011
1
COAs
96.8%
Avg purity
1
Labs
A randomized, double-blind pilot trial (Hauser et al., Movement Disorders, 2009, PMID 19230029) tested IV glutathione 1,400 mg three times weekly for 4 weeks in Parkinson's disease (n=21); it was well tolerated but did NOT show a statistically significant effect on UPDRS scores. A large randomized trial of inhaled glutathione (646 mg every 12 hours for 6 months) in cystic fibrosis (Griese et al., Am J Respir Crit Care Med, 2013, PMID 23631796) did not demonstrate clinically relevant improvements in lung function, exacerbations, or quality of life. Oral glutathione has poor bioavailability due to GI degradation, driving investigation of IV, nebulized, liposomal, and sublingual delivery. The FDA issued a 2019 warning about compounded sterile injectable glutathione made from dietary-grade ingredient, citing adverse-event reports (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and kidney dysfunction) particularly in the context of unregulated IV skin-lightening use.
Key references
In diet-induced obese mice (intraperitoneal dosing), SR-9011/SR9009 increased energy expenditure, reduced fat mass, and improved dyslipidemia and hyperglycemia (Solt et al., Nature 2012). Human liver microsome work identified 14 metabolites but no half-life, and the authors caution against human extrapolation. There are no registered human trials of SR-9011; no human safety, dose, or pharmacokinetic data exist.
Glutathione (Immune) and SR-9011 (Metabolic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs